Abstract
There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus-infected (HIV+) individuals receiving antiretroviral therapy. In a two-step intensive sampling pharmacokinetic trial, we compared the area under the concentration-time curve from 0 to 28 days (AUC0-28) of an active metabolite of amodiaquine, desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-naive HIV+ adults and those taking nevirapine and ritonavir-boosted lopinavir-based antiretroviral therapy. In step 1, malaria-uninfected adults (n = 6/arm) received half the standard adult treatment regimen of artesunate-amodiaquine. In step 2, another cohort (n = 25/arm) received the full regimen. In step 1, there were no safety signals or significant differences in desethylamodiaquine AUC0-28 among participants in the ritonavir-boosted lopinavir, nevirapine, and antiretroviral therapy-naive arms. In step 2, compared with those in the antiretroviral therapy-naive arm, participants in the ritonavir-boosted lopinavir arm had 51% lower desethylamodiaquine AUC0-28, with the following geometric means (95% confidence intervals [CIs]): 23,822 (17,458 to 32,506) versus 48,617 (40,787 t...Continue Reading
References
Apr 1, 1991·Gut·W H PetersP G Kremers
Jan 1, 1991·International Archives of Allergy and Applied Immunology·J B ClarkeB K Park
Jun 1, 1990·British Journal of Clinical Pharmacology·P A WinstanleyA M Breckenridge
Mar 19, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·L I Malaty, J J Kuper
Sep 29, 2000·Lancet·J WhitworthA Ojwiya
Jan 24, 2002·The Journal of Pharmacology and Experimental Therapeutics·Xue-Qing LiCollen M Masimirembwa
Apr 3, 2003·HIV Clinical Trials·Luz Martín-CarboneroVincent Soriano
Oct 1, 2003·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·L S Fridericia
Apr 20, 2004·AIDS·Kate GrimwadeCharles F Gilks
Apr 21, 2004·The Journal of Clinical Psychiatry·Pieter J HoekstraRuud B Minderaa
Feb 18, 2005·The Journal of Infectious Diseases·Ian SanneFranck Rousseau
Jun 17, 2005·AIDS·Saye KhooPeter Winstanley
Oct 29, 2005·BMC Clinical Pharmacology·Ina BergheimAlexandr Parlesak
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheryl CohenHeather Crewe-Brown
Feb 16, 2006·The Journal of Infectious Diseases·Miriam K LauferChristopher V Plowe
Sep 9, 2006·The Journal of Infectious Diseases·Jean-Pierre Van GeertruydenUmberto D'Alessandro
Oct 21, 2006·AIDS·Kirsten HewittNeil French
Feb 17, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Polina GermanFrancesca T Aweeka
Jul 11, 2007·Journal of Pharmacokinetics and Pharmacodynamics·Sofia Friberg HietalaMichael Ashton
Jan 16, 2008·Clinical Pharmacokinetics·Polina I German, Francesca T Aweeka
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anne F GasasiraGrant Dorsey
Sep 10, 2008·Antimicrobial Agents and Chemotherapy·George O AdjeiJorgen A L Kurtzhals
May 1, 2009·Emerging Infectious Diseases·Victor ChalweUmberto D'Alessandro
May 1, 2009·European Journal of Clinical Pharmacology·Visweswaran NavaratnamPiero Olliaro
May 30, 2009·Archives of Toxicology·Shinji ShimizuOsamu Okazaki
Aug 21, 2009·Malaria Journal·Kasia StepniewskaJean-René Kiechel
Oct 21, 2009·Antimicrobial Agents and Chemotherapy·Julia MwesigwaFrancesca Aweeka
Dec 28, 2010·Malaria Journal·Chris LourensNiklas Lindegardh
Jun 29, 2011·Antimicrobial Agents and Chemotherapy·Marcus J RijkenFrançois Nosten
Jan 22, 2014·The Journal of Antimicrobial Chemotherapy·Kimberly K ScarsiSunil Parikh
Apr 19, 2015·BMC Medicine·UNKNOWN WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study GroupIssaka Zongo